Cefazolin All Strengths — supply status, manufacturers & alternatives

Cefazolin All Strengths

—

In supply · Australia

In supply · 🇦🇺 Australia · short in🇨🇦 CA🇺🇸 US

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Controlled substance
Active ingredient (INN)	Cefazolin All Strengths
Therapeutic category	Auto-created by FDA Drug Enforcement — Full Recall Database scraper

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Recalls official enforcement reports

🇨🇦

CEFAZOLIN FOR INJECTION USP 10 G / VIAL

Drugs and health products · Feb 2026

Class Idetails ↗

🇺🇸

Cefazolin Sodium In Sterile Water For Injection

Wells Pharma of Houston LLC · Nov 2023

Class IIdetails ↗

🇺🇸

CEFAZOLIN SODIUM

Mckesson Medical-Surgical Inc. Corporate Office · Apr 2022

Class IIdetails ↗

🇺🇸

CEFAZOLIN SODIUM

Mckesson Medical-Surgical Inc. Corporate Office · Apr 2022

Class IIdetails ↗

🇨🇦

Cefazolin for Injection (2017

Drugs and health products · June 2017

Class Idetails ↗

🇺🇸

Cefazolin All Strengths

Advanced Pharma Inc. · Feb 2017

Class IIdetails ↗

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.